News and Trends 15 Mar 2018 French VC Raises the Biggest Green Biotech Fund in the World Update (15/03/2018): Sofinnova Partners has closed its fund Industrial Biotech I at €125M, making it the largest fund dedicated to driving the transition towards a more sustainable fund. 03/03/2017 Sofinnova Partners has announced the first closing of a new fund, dedicated to renewable chemistry in industrial biotech, at €106 million. The largest biotech VC in […] March 15, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Mar 2018 This Swedish Discovery Could Change the Way We Treat Diabetes Swedish researchers have found that insulin-producing cells alone are not enough to fine-tune blood sugar levels. This could change the way diabetes treatments are designed. While it is known that certain clusters of cells in the pancreas called pancreatic islets influence the set point for blood sugar, the exact mechanisms are still unknown. The control of […] March 15, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 15 Mar 2018 Can MorphoSys’ Alzheimer’s Treatment Work Where Big Pharma has Failed? Roche has positive clinical data in support of starting a Phase III trial in Alzheimer’s with an antibody initially developed by MorphoSys. However, the field is full of similar approaches that have failed. Roche plans to start a Phase III study to test MorphoSys’ Alzheimer’s treatment gantenerumab later this year, after encouraging preliminary clinical results. The drug […] March 15, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Inside Labiotech 15 Mar 2018 Why is Victor Dillard, Founder of Desktop Genetics, reading Labiotech.eu? Leaders & Readers: I had a chat with Victor Dillard about why he reads Labiotech.eu. He’s the COO/CFO, and Founder of Desktop Genetics, a leader in genome editing technology that aims to help researchers discover and treat the root genetic cause of human disease. This interview has just been lightly edited for grammar. Why and how […] March 15, 2018 - 2 minutesmins - By Katherine Douglas Share WhatsApp Twitter Linkedin Email
News and Trends 15 Mar 2018 New Antibiotic for MRSA Infections is Ready for US Clinical Trials Update (15/03/2018): The FDA has granted Fast Track Designation to XF-73, an antibody being developed by Destiny Pharma against post-surgical MRSA infections. Originally published on 26/02/2018 Destiny Pharma’s antibiotic for post-surgical infections will begin its clinical development after the FDA accepted its Investigational New Drug application. Destiny Pharma wants to combat the growing antibiotic resistance […] March 15, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 14 Mar 2018 A New Drug for Atrial Fibrillation Starts Human Testing in Europe Update (14/03/2018): Acesion Pharma has started a Phase I clinical trial at the Centre for Human Drug Research (CHDR) in the Netherlands. The trial will test AP30663, a treatment for atrial fibrillation that the company believes has the potential to work better than every option currently available. Originally published on 2/8/2018 The Danish biotech Acesion Pharma […] March 14, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Mar 2018 French Biotech Restores Vision in Humans with Subretinal Implant Pixium Vision has successfully restored vision in three patients with age-related macular degeneration (AMD) using an implanted wireless device, offering significant improvements to their quality of life. Pixium Vision has restored vision in three patients with age-related macular degeneration (AMD), using a wireless microchip, named PRIMA, that is implanted under a patient’s retina. The technology marks a […] March 13, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 13 Mar 2018 Danish Biotech Collaborates With US Merck on Combination Therapy for Lung Cancer IO Biotech will test its immune modulator in combination with Merck’s checkpoint inhibitor Keytruda, known for curing former US President Jimmy Carter’s cancer. IO Biotech, based in Copenhagen, has entered an agreement with Merck (the US one) to enter a Phase I/II trial for treating lung cancer with IO’s immune modulator, IO102, and Merck’s checkpoint […] March 13, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 13 Mar 2018 This Oxford Spin-out Could be Printing New Body Parts The Oxford spin-out OxSyBio has secured £10M (€11,26M) to develop a 3D tissue printer that uses liquid droplets to design and regenerate tissues. Founded in 2014, OxSyBio is developing a technology to 3D print living tissues in order to replace body parts that are damaged by disease or injury. The substantial Series A funding was provided by Woodford Investment […] March 13, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 13 Mar 2018 French Biotech Takes its Oral Diabetes Drug to Phase III Update (13/03/2018): Poxel has started two more Phase III trials in Japan testing its drug for type 2 diabetes, imeglimin. This oral drug has shown potential to lower glucose levels thanks to a mechanism of action that targets the pancreas, the liver and muscles simultaneously. The new trials will confirm whether these effects are maintained in a larger […] March 13, 2018 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
In Depth 13 Mar 2018 The Most Important Battle in Gene Editing: CRISPR versus TALEN Despite all the hype, CRISPR is still not in the clinic as a standalone therapy or part of another. So where is it in biotech? CRISPR needs no introduction. Since the gene editing technology first entered the spotlight in 2012 with the promise of revolutionizing gene editing, it has made headlines as the subject of a furious […] March 13, 2018 - 6 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 12 Mar 2018 FDA Says Dutch Surgical Sealant Patch Could Save Lives Polyganics has received a Breakthrough Device Designation from the FDA for its biodegradable sealant patch for surgical wounds. Polyganics, based in Groningen, the Netherlands, specializes in medical devices that use natural polymers to help regenerate injured tissue. The FDA granted a Breakthrough Device Designation for its Liver and Pancreas Sealant Patch. The patch uses Polyganics polymer technology to seal […] March 12, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email